Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206142 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL3628141 | 0.89 | MEN1 (0.47) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL26910995 | 0.85 | KMT2A (0.64) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL5787755 | 0.84 | KDR (0.47) | KMT2AMEN1KDRHPGDALDH1A1 | |
| SCHEMBL221242 | 0.84 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL29391624 | 0.84 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL4902982 | 0.83 | SMN1; SMN2 (0.52) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL11133606 | 0.82 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL6574416 | 0.82 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERKDR | |
| SCHEMBL6175584 | 0.82 | KMT2A (0.73) | KMT2AMEN1MAPK10GFERKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150994-A1 | METHODS FOR SYNTHESIS OF CHK1 INHIBITORS | SIERRA ONCOLOGY, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150994-A1 | METHODS FOR SYNTHESIS OF CHK1 INHIBITORS | SIERRA ONCOLOGY, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| EP-3463348-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | Karus Therapeutics Ltd (GB) | 2019-04-10 | — | — | EP | disclosed |
| EP-3456355-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3456355-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2004004730-A2 | 2-AMINOPYRAZINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150994-A1 | METHODS FOR SYNTHESIS OF CHK1 INHIBITORS | CHEK1, CHEK2, CDC7 | KMT2A 2137/4885MEN1 1192/4885MAPK10 1704/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | KMT2A 538/4885MEN1 3865/4885MAPK10 1628/4885 |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, BUB1B | KMT2A 841/4885MEN1 2356/4885MAPK10 997/4885 |
| US-10870624-B2 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC2 | KMT2A 46/4885MEN1 3448/4885MAPK10 761/4885 |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | MCL1, HDAC1, MYC | KMT2A 188/4885MEN1 1396/4885MAPK10 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.